AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19365587
Drug: Clopidogrel 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 450 mg loading and 75 mg/d thereafter added to standard reperfusion therapy (group 2, n: 85)
Trial: 17460488
Drug: Lactobacillus LB
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus LB (Lacteol) plus oral rehydration salts (ORS)
Trial: 17460488
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus oral rehydration salts (ORS)
Trial: 9133767
Drug: Venlafaxine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine and therapy
Trial: 9133767
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and therapy
Trial: 8432296
Drug: Alteplase (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (10 mg bolus injection + 5000 IU heparin bolus injection, followed by 90 mg alteplase over 3 h)
Trial: 8432296
Drug: Anistreplase (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anistreplase (30 mg iv over 5 min)
Trial: 17868006
Drug: Zonisamide (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide (50-100 mg/day)
Trial: 12135034
Drug: 68 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68 g polyethylene glycol (PEG) laxative
Trial: 10426889
Drug: Proprietary base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary base cream
Trial: 7546114
Drug: Non-thermal pulsed
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-thermal pulsed high-frequency electromagnetic energy treatment for 30 minutes twice daily for 12 weeks
Trial: 7546114
Drug: Non-thermal pulsed
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-thermal pulsed high-frequency electromagnetic energy treatment
Trial: 766142
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg)
Trial: 4042525
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg and 100 mg combined)
Trial: 29275880
Drug: Candesartan with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan with hydrochlorothiazide (HCTZ; 16 mg/12.5 mg/d)
Trial: 16990190
Drug: Hydroxocobalamin (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxocobalamin (2.5, 5, 7.5, or 10 g intravenous doses)
Trial: 11020518
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist combined with FSH
Trial: 1977703
Drug: Antacids
RxNorm normalized name: ANTACIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids
Trial: 6985989
Drug: Tolbutamide treatment
RxNorm normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolbutamide treatment
Trial: 31564269
Drug: Incentive spirometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentive spirometry (ISM) with steam inhalation and nebulization with beta 2 agonist for 15-20 minutes for 35-45 minutes twice daily for 7 days
Trial: 19702079
Drug: SFI 1
RxNorm normalized name: Salmeterol Fluticasone Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFI 1 mL/kg after intubation and before blocking the aorta (Group E1)
Trial: 19702079
Drug: SFI 1
RxNorm normalized name: Salmeterol Fluticasone Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFI 1 mL/kg after opening the aorta (Group E2)
Trial: 19702079
Drug: SFI 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFI 0.5 mL/kg twice, before blocking and after opening the aorta (Group E3)
Trial: 19702079
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 1 mL/kg after intubation (Group C)
Trial: 16551919
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block with 0.25% bupivacaine 15 mL on each side
Trial: 12571670
Drug: Exposure-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based intervention (tasting sweet red pepper for 8 daily sessions)
Trial: 9331228
Drug: 0.50 mg
RxNorm normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg oral alprazolam
Trial: 2441631
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose epidural anesthesia with 2% lidocaine-0.2% tetracaine
Trial: 16702981
Drug: Lisinopril (L)
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril (L)
Trial: 28940451
Drug: Vilaprisan 1
RxNorm normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan 1 mg/day
Trial: 28940451
Drug: Vilaprisan 4
RxNorm normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan 4 mg/day
Trial: 28940451
Drug: Vilaprisan ≥1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan ≥1 mg/day
Trial: 21688876
Drug: Daily estimated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily estimated blood alcohol concentration (eBAC)
Trial: 17962423
Drug: Osmotic-controlled extended-release
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotic-controlled extended-release methylphenidate (108 mg)
Trial: 17962423
Drug: Osmotic-controlled extended-release
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotic-controlled extended-release methylphenidate (54 mg)
Trial: 17962423
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (50 mg)
Trial: 12228819
Drug: Atovaquone/proguanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone/proguanil (1 Malarone tablet per day for 20 weeks; n=148)
Trial: 7821106
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg isosorbide dinitrate
Trial: 27052634
Drug: Acarbose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (100 mg three times a day)
Trial: 2687557
Drug: Capoten monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capoten monotherapy
Trial: 2687557
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with glycosides and saluretics
Trial: 3430953
Drug: Furosemide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (mean dose = 172 mg)
Trial: 26891756
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg twice daily added to aspirin 81 mg/day
Trial: 26891756
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to aspirin 81 mg/day
Trial: 22434340
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g diluted in 10 ml of lidocaine 1% administered periprostatically and ciprofloxacin orally
Trial: 22434340
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml lidocaine 1% administered before TRUS gpb
Trial: 2405920
Drug: Serum beta
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum beta 2 microglobulin levels ≥ 6 micrograms/mL
Trial: 6986896
Drug: Intranasal flunisolide
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal flunisolide (300 microgram/day)
Trial: 24468920
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy with sudden gains
Trial: 22694829
Drug: Ipilimumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (3 mg/kg q3w x 4 doses) + placebo
Trial: 22694829
Drug: gp100 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp100 vaccine + placebo
Trial: 17300626
Drug: Once-daily regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily regimen of artemether-lumefantrine (AL) with 200 ml flavoured milk for 3 days
Trial: 17300626
Drug: Conventional twice-daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional twice-daily regimen of artemether-lumefantrine (AL) with 200 ml flavoured milk for 3 days
Trial: 17300626
Drug: Six-dose arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six-dose arm (twice-daily regimen)
Trial: 17300626
Drug: Three-dose arm
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose arm (once-daily regimen)
Trial: 12845653
Drug: Antihistamine users
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine users
Trial: 9869600
Drug: Fedotozine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fedotozine (100 mg intravenous infusion)
Trial: 2072147
Drug: Individualized dosing
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dosing of etoposide (target WBC nadir of 1,700/microL)
Trial: 2072147
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of etoposide (125 mg/m2/d)
Trial: 28931149
Drug: B-GOS (2.7g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-GOS (2.7g daily for 7-15 days)
Trial: 22468907
Drug: Therapist adherence
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist adherence to concrete cognitive therapy techniques
Trial: 12564664
Drug: Otic powder
RxNorm normalized name: Primadophilus Reuteri Probiotic Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otic powder (Auricularum)
Trial: 7534331
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 micrograms subcutaneously, twice daily for 4 weeks)
Trial: 2361714
Drug: Rice water
RxNorm normalized name: CVS Electrolyte Solution with Zinc (Rice Water)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice water electrolytes solution
Trial: 375343
Drug: BAY g
RxNorm normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY g 5421 (Acarbose) 50 mg
Trial: 21890887
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 10 mg
Trial: 21890887
Drug: Isobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric bupivacaine 10 mg
Trial: 21890887
Drug: Hypobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypobaric bupivacaine 10 mg
Trial: 18984669
Drug: Hyperinsulinemic euglycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic euglycemic clamp with LPS (insulin infusion at 10 or 40 mU.m(‐2).min(‐1))
Trial: 28393773
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (Dex) 0.5 μg/kg/h
Trial: 24267363
Drug: Oral desensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral desensitization (200 mL of cow's milk daily)
Trial: 22122955
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) administered perorally after shooting
Trial: 8895046
Drug: Nimodipine monotherapy
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine monotherapy
Trial: 9790159
Drug: Nimodipine with
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine with carbamazepine augmentation
Trial: 9790159
Drug: Nimodipine-carbamazepine combination
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine-carbamazepine combination
Trial: 2561036
Drug: metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol (200 mg/die)
Trial: 2561036
Drug: combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined therapy with atenolol (50 mg) and nifedipine (20 mg)
Trial: 2561036
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg acebutolol and 20 mg nifedipine
Trial: 2561036
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg atenolol and 10 mg enalapril
Trial: 2561036
Drug: all treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all treatments
Trial: 21855244
Drug: Boswellia serrata
RxNorm normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boswellia serrata gum resin extracts (BSE) at a high dose of 4200 mg per day
Trial: 17274236
Drug: Herbal mouthwash
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal mouthwash containing the pericarp extract of Garcinia mangostana L
Trial: 23359265
Drug: Nevirapine 200
RxNorm normalized name: nevirapine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine 200 mg once-daily regimen
Trial: 27849643
Drug: Diclofenac (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (100 mg)
Trial: 8376274
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg)
Trial: 27275104
Drug: Naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg)
Trial: 26615516
Drug: Esmolol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (500 mcg/kg bolus 10 min before induction, followed by 200 mcg/kg/min infusion)
Trial: 22954393
Drug: Half-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose tirofiban (5 μg/kg bolus, 0.075 μg/kg/min infusion for 48 h)
Trial: 22954393
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Standard-dose and Half-dose tirofiban)
Trial: 20803038
Drug: Palliative therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative therapies
Trial: 15168037
Drug: Eccentric exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric exercise followed by a CHO-rich diet (> 10 g/kg body mass/24 h)
Trial: 9853438
Drug: Topical recombinant
RxNorm normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical recombinant bovine basic fibroblast growth factor (rbFGF) 150 AU/cm2 daily
Trial: 29723874
Drug: Warfarin (anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (anticoagulant continued)
Trial: 29723874
Drug: Lower-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose edoxaban regimen (LDER) (anticoagulant continued)
Trial: 8893110
Drug: Hydroxyzine 25
RxNorm normalized name: hydroxyzine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 25 mg tid
Trial: 6148843
Drug: Dynamically oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamically oriented supportive therapy (ST)
Trial: 24439238
Drug: Day patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day patient treatment (DP) after 3 weeks of inpatient care
Trial: 29222135
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment (IP)
Trial: 22823994
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment + SABR to all sites of known disease
Trial: 22823994
Drug: Current standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current standard of care treatment
Trial: 17460714
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily ramipril 10 mg
Trial: 17460714
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily ramipril 5 mg
Trial: 12475452
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone for 45 days
Trial: 9972754
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (25-200 microg)
Trial: 12676276
Drug: Calcium appetite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium appetite related to perturbed calcium metabolism
Trial: 25556427
Drug: Metformin (500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500mg Bid)
Trial: 25556427
Drug: Megestrol (40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megestrol (40mg daily)
Trial: 23871290
Drug: Heparin thromboprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin thromboprophylaxis
Trial: 3545941
Drug: Co-trimoxazole twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole twice daily
Trial: 24704505
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated tetravalent bovine-human reassortant rotavirus vaccine (BRV-TV)
Trial: 15820074
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (intraoperative hypotonic peritoneal chemo-hyperthermia and early postoperative intraperitoneal chemotherapy)
Trial: 15820074
Drug: Treatment groups
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment groups 1 and 2 (combined therapy and intraoperative chemotherapy)
Trial: 12549803
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (10 mg/kg/dose for three doses given at 24 hourly intervals)
Trial: 12549803
Drug: Indomethacin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.2 mg/kg/dose for three doses given at 12 hourly intervals)
Trial: 12549803
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen and Indomethacin
Trial: 15662995
Drug: Albendazole 1200
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 1200 mg
Trial: 7858933
Drug: MTC 40
RxNorm normalized name: MTC-DOX
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MTC 40 mg by nasal spray 2 h before chemotherapy, followed by the same dose at 4 h and 8 h (nasal spray)
Trial: 2488281
Drug: Zidovudine (AZT);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (AZT); specific dosage and duration not mentioned
Trial: 31073189
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) elements
Trial: 28552257
Drug: Nebulized liposomal
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized liposomal amphotericin B (LAmB) maintenance therapy
Trial: 28552257
Drug: Conventional strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional strategy without antifungal maintenance therapy
Trial: 21348793
Drug: Cilostazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (200 mg/day) for 8 weeks
Trial: 19731700
Drug: Lifestraw Personal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestraw Personal water treatment device
Trial: 15019322
Drug: Topical 0.05%
RxNorm normalized name: ingenol topical 0.05% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.05% cyclosporin A eyedrops
Trial: 11262208
Drug: pyrimethamine‐sulfadoxine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrimethamine‐sulfadoxine and 3 doses of artesunate
Trial: 9272590
Drug: Hypoglycaemia (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia (at around 3 mmol l(‐1))
Trial: 2459655
Drug: Bovine surfactant
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bovine surfactant treatment
Trial: 2126475
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no surfactant treatment)
Trial: 3563430
Drug: Sulfadiazine-trimethoprim combination
RxNorm normalized name: sulfadiazine / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadiazine-trimethoprim combination (500 mg + 150 mg) b.i.d. for 3 days
Trial: 3563430
Drug: Sulfadiazine-trimethoprim combination
RxNorm normalized name: sulfadiazine / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadiazine-trimethoprim combination (500 mg + 150 mg) b.i.d. for 10 days
Trial: 3563430
Drug: Pivmecillinam (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam (500 mg) t.i.d. for 3 days